AbbVie Q1 2026 Earnings Beat Driven by Skyrizi and Rinvoq
AbbVie (ABBV) reported Q1 2026 earnings that beat analyst estimates, driven by robust sales growth of Skyrizi and Rinvoq, which offset the continued decline of Humira and led to an upward revision of 2026 guidance.
Key Numbers
AbbVie (ABBV) reported first-quarter 2026 results that surpassed analyst expectations, fueled by strong sales growth of its immunology drugs Skyrizi and Rinvoq. The growth offset the ongoing decline of Humira, prompting the company to raise its full-year 2026 guidance.
Key Financial Results
| Metric | Q1 2026 | YoY Change |
|---|---|---|
| Revenue | Not disclosed | Not disclosed |
| Net Income | Not disclosed | Not disclosed |
| EPS | Not disclosed | Not disclosed |
Note: The company did not disclose absolute figures but confirmed the beat.
Key Highlights
- Skyrizi and Rinvoq: Recorded strong sales growth, offsetting the sharp decline in Humira revenue.
- Humira: Continued to decline due to biosimilar competition.
- Guidance: AbbVie raised its full-year 2026 guidance.
Future Guidance
AbbVie raised its 2026 guidance, expecting stronger performance than previously estimated, though no specific numbers were provided.
Stock Impact
The source did not mention immediate stock reaction, but earnings beats and guidance raises are typically viewed positively.
What This Means for Investors
This report demonstrates AbbVie's ability to offset Humira's decline with its newer drugs, boosting confidence in the company's long-term strategy. However, the sustainability of Skyrizi and Rinvoq growth amid competition remains key.
Frequently Asked Questions
Found this useful? Share it